COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
Article 2021 en
Authors
CA
Chiara Agrati
SC
Serena Di Cosimo
DF
Daniela Fenoglio
Abstract
1 min read
Patients diagnosed with malignancy, neurological and immunological disorders, <i>i.e.</i>, fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.
Kate Stevens, Eleni Frangou, Jae Il Shin, Hans‐Joachim Anders, Annette Bruchfeld, Ulf Schönermarck, Thomas Häuser, Kerstin Westman, Gema Fernández‐Juárez, Jürgen Floege, Dimitrios Goumenos, Kültiğin Türkmen, Cees van Kooten, Stephen P. McAdoo, Vladimı́r Tesař, Mårten Segelmark, Duvuru Geetha, David Jayne, Andreas Kronbichler
Evangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, Chara Giatra, Ioannis Asimakopoulos, Maria Dimou, Aimilia D. Sklirou, Ioannis Ntanasis‐Stathopoulos, Ismini Darmani, Αlexandros Briasoulis, Efstathios Kastritis, Maria K. Angelopoulou, Ioannis Baltadakis, Panayiotis Panayiotidis, Ioannis P. Trougakos, Theodoros P. Vassilakopoulos, Maria Pagoni, Meletios A Dimopoulos
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.